Quarter and Full-Year Financials
Q4 total revenue of $836 million and non-GAAP operating income of $366 million. Full-year revenue of $3.195 billion and non-GAAP operating income of $1.434 billion. Management highlighted having surpassed the $3 billion revenue run-rate goal for the year.
Strong Profitability
Non-GAAP operating margin is roughly in the mid-40s (~45% reported by management), reflecting continued high operating leverage and profitable execution across software and services.
Guidance and Top-Line Outlook
Company provided FY2027 revenue guidance implying approximately 13% total revenue growth. Management expects normalized billings to be provided annually (11% growth referenced versus subscription growth) and seasonality similar to prior years.
Subscription and Billings Dynamics
Management discussed subscription growth of ~13% for FY2027 versus normalized billings growth of ~11%, driven by product mix shifts (growth moving from mature products like eTMF toward faster-growing, earlier-stage products such as RTSM, EDC, safety and LIMS) and tougher compares in Crossix.
Commercial Momentum — Vault CRM
Vault CRM momentum with ~140 customers live (management previously noted 125+ and updated to ~140). Expectation that ~14 of the top 20 life sciences companies will standardize on Vault CRM over time; several top-20 projects are already active and executing.
R&D Product Wins and Enterprise Deals
Significant top-20 wins in RTSM and safety, including a top-20 standardizing on RTSM and first top-20 go-lives on Signal and Workbench. Management described RTSM as a large product area comparable in significance to EDC and highlighted long-term ramp potential.
Crossix and Commercial Data Strength
Crossix had an outstanding fiscal 2026 and was a major driver of outperformance; the team is described as executing well with a long runway for growth (management cautioned compares will be tougher into FY2027).
Professional Services Execution
Professional services outperformed, driven by business consulting, R&D services, digital events and CRM migration work. Management has been hiring to support demand and expects the services margin profile to remain healthy.
AI Strategy and Early ROI Proof Points
Company emphasized AI as an important strategic area with early, concrete ROI in commercial content automation (faster content creation and lower content costs). Veeva is positioned as a trusted provider for industry-specific AI applications and is a launch partner on initiatives like Claude for Life Sciences.
Study-by-Study (CRO) Opportunity
Management reiterated a strategic push into the CRO/study-by-study channel (OEMing Veeva technology to CROs) and views the combined study-by-study opportunity across EDC, RTSM, eCOA as large (potentially up to ~$1B opportunity by internal estimates) with new go-to-market emphasis.
Customer Growth and Execution in SMB/Biotech
Customer count growth accelerated to ~5% year-over-year, driven by strong execution in the basics offering for small emerging biotechs and cross-sell opportunities (Network, OpenData, Service Center, Campaign Manager).